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ABSTRACT
Pancreatic metastases are rare; they account for only 2% of all pancreatic malignancies and usually occur when 
associated with a disseminated metastatic disease. Solitary pancreatic metastases are even less frequent, and there are 
few reports regarding surgical resection. We report the case of a 77-year-old female patient diagnosed with a single 
cephalo-pancreatic metastasis of renal cell carcinoma, 16 years after a total nephrectomy. The patient underwent successful 
pancreaticoduodenectomy, and the diagnosis was confirmed. A subsequent positron emission tomography (PET) scan 
showed disease relapse, and tyrosine kinase inhibitor treatment with sunitinib was initiated. After 1 year and 4 months, 
the PET-computed tomography scan showed a complete radiologic response. 
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CASE REPORT
A 77-year-old female patient sought medical care 
complaining of vague, mild, and non-specific abdominal 
pain for the past week. The physical examination 
and laboratory blood tests were unremarkable. 
Her medical history included a total left nephrectomy 
due to a renal cell carcinoma (RCC) diagnosed 16 years 
ago (pathological stage pT1N0M0), cholelithiasis, 
controlled arterial hypertension, and an ischemic stroke 
episode 10 years ago without major physical restraints.
The contrast-enhanced abdominal computed 
tomography (CT) scan was performed, showing a 
single cephalo-pancreatic nodule, isodense with the 
pancreas on the non-contrast-enhanced images, 
markedly hypervascular on the arterial phase, and 
slightly hyperdense compared with the pancreas on 
the portal-venous phase (Figure 1).
At magnetic resonance imaging (MRI), the nodule 
was hyperintense on T2-weighed images relative to 
the normal pancreas, showing a more hyperintense 
central area, representing cystic/necrotic changes. 
On T1-weighed fat saturated images, the nodule 
was slightly hypointense compared to the normal 
pancreatic parenchyma. On diffusion-weighted 
images, a mild restriction could be noted. The contrast 
uptake dynamics were similar to the CT scan; also, on 
the delayed phase, a thin hyperintense capsule was 
noted (Figure 2).
As  there  wasn ’t  any  o ther  ev idence  of 
extrapancreatic disease, the patient was submitted 
to a pancreaticoduodenectomy 10 months after the 
initial CT scan. The surgical specimen showed a 15 mm 
cephalo-pancreatic brownish nodule, with central 
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cystic/necrotic changes and a surrounding thin fibrous 
capsule (Figures 3 and 4).
The histological study with hematoxylin and 
eosin (H&E) staining revealed alveolar growth of large 
polygonal cells with clear cytoplasm, uniform round 
nuclei, and inconspicuous nucleoli, surrounded by a 
fibrous capsule (Figure 4).
Figure 1. Abdominal CT, axial plane. A – A single nodular lesion in the pancreatic head; B – markedly hypervascular 
on the arterial phase (arrowhead).
Figure 2. Abdominal MRI. A –T2-weighted sequence shows a hyperintense pancreatic nodule (arrowhead); 
B and C – The contrast uptake dynamics was similar to the CT scan; D – On the delayed phase, note a thin 
hyperintense capsule.
Immunohistochemical study showed positivity for 
CAM 5.2 and CD10, and was negative for synaptophysin, 
Ck7, vimentin, and CD117. These findings were 
compatible with clear cell renal carcinoma pancreatic 
metastasis (Figure 5). The Memorial Sloan-Kettering 
Cancer Center score for metastatic RCC yielded 0 points, 
classifying the patient in a favorable risk group.
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on the remaining pancreatic parenchyma, with an 
increase in standardized uptake value from the early 
to the delayed phase. We believe this was consistent 
with residual metastatic disease, which was not 
Figure 3. Gross view of the surgical specimen of cephalic duodenopancreactectomy showing a pancreatic nodule 
(arrowhead) with central cystic/necrotic changes (asterisk).
Figure 4. A – Photomicrography of the tumor showing large polygonal cells with clear cytoplasm (white asterisk) 
with a surrounding fibrous capsule (white arrowhead). Note the cystic/necrotic part of the tumor (black asterisk) 
(H&E, 20X); B – MRI representation of the cystic/necrotic changes within the nodule, which appear bright on 
T2-weighted images (arrowhead); C – with decreased contrast uptake (arrowhead); D – The delayed phase shows 
the late enhancement of the nodule surrounding the fibrous capsule (arrowhead).
Fludeoxyglucose (FDG) positron emission 
tomography (PET)-CT scan was performed 1 month 
and 11 days after surgery to exclude residual disease. 
It showed several foci with a very high FDG uptake 
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Figure 6. PET scan. A – Nodular hyperfixation area of FDG on the remaining parenchyma (white arrow); B – At 1 year 
and 4 months follow-up, the PET-CT scan showing no signs of disease relapse.
Figure 5. Photomicrography of the tumor. A – Alveolar growth of large polygonal cells with clear cytoplasm, 
uniform round nuclei, and inconspicuous nucleoli (white asterisk), surrounded by a thin fibrous capsule (arrowhead) 
and normal pancreatic tissue (black asterisk) (H&E, 100x); B–D – The immunohistochemical study shows positivity 
for CAM 5.2 and CD10, and negativity for synaptophysin.
conspicuous on surgery (Figure 6A). Tyrosine kinase 
inhibitor treatment with sunitinib 50 mg a day was 
then initiated: 4 weeks on, 2 weeks off. After 1 year 
and 4 months, the PET-CT scan showed no signs 
of disease, which was consistent with a complete 
radiological treatment response (Figure 6B).
DISCUSSION
Pancreatic metastases are rare, accounting for 
only 2% of all pancreatic malignancies.1
The most common tumors that metastasize 
to the pancreas are RCC, melanoma, breast 
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cancer, lung cancer, gastric cancer, and colorectal 
carcinoma.2,3 The metastatic pancreatic disease 
is often asymptomatic, and is usually detected 
during disease follow-up.1 When symptomatic, the 
manifestations may include abdominal pain, nausea, 
weight loss, and gastrointestinal bleeding. Pancreatic 
duct obstruction may also occur, leading to jaundice 
or acute pancreatitis.3
Pancreatic metastases follow three major patterns: 
(i) single localized mass in 50%-73% of cases; (ii) diffuse 
pancreatic enlargement (15%-44%); and (iii) multiple 
pancreatic nodules (5%-10%). No predominance of a 
distinct part of the pancreas has been reported to be 
affected by the metastases, and the lesions’ pattern 
of enhancement on CT or MRI tend to mimic that 
of a primary tumor.3-5 Metastases from pulmonary, 
gastric, and colorectal adenocarcinoma are normally 
hypovascular, mimicking the pattern of enhancement 
of pancreatic adenocarcinoma. RCC metastases tend to 
appear as hypervascular on the arterial phase reflecting 
a viable tumor, with decreased or absent perfusion 
centrally, representing necrosis—a feature that is also 
typical of primary RCC.6
Pancreatic metastases do not usually represent 
a challenging diagnosis as they normally develop late 
in the presentation of a known primary malignancy. 
An exception is RCC, which is notable for metastasizing 
long after the diagnosis and treatment of the primary 
tumor, with a mean interval between primary RCC and 
pancreatic metastasis of 8–10 years.7-9 It is believed that 
the pancreas is affected by more indolent variants of 
RCC, representing a favorable subgroup of patients 
with tumor recurrence.10,11
In the case of our patient with previous RCC and a 
solitary hypervascular nodule, apart from the diagnosis 
of metastatic malignancy, the differential diagnosis 
included a pancreatic metastasis from a synchronous 
primary RCC in the contralateral kidney, a pancreatic 
neuroendocrine tumor, vascular lesions (as aneurysms 
of the splenic artery), or accessory intrapancreatic 
spleens.12 A synchronous primary RCC was ruled out as 
the contralateral kidney was normal at CT scan and MRI. 
The lesion appearance at imaging was not suggestive of 
an aneurysm, and an accessory intrapancreatic spleen 
was not very probable as the spleen did not present any 
significant changes. In this case, the most reasonable 
diagnosis would be a pancreatic neuroendocrine 
tumor or metastasis from the previous RCC. When the 
diagnosis is uncertain, percutaneous or endoscopic 
ultrasound-guided biopsy may be useful, since its 
diagnostic accuracy may reach 90%.6,13
Surgery is usually not viable due to the disseminated 
metastatic disease, and tyrosine kinase inhibitors (TKI), 
immunotherapy, and palliative care are the most 
appropriate treatments. First-line therapy usually consists 
of TKI or an anti-vascular endothelial growth factor 
antibody, being sunitinib or pazopanib, and bevacizumab 
plus interferon-alfa2a, which are the drugs most 
commonly used, respectively. Second-line therapy has 
been recently changed with nivolumab (anti-programmed 
death 1 inhibitor) and cabozantinib (TKI) showing very 
significant improvement in overall survival.14
Experience in managing patients with pancreatic 
RCC metastases is limited, and decisions should 
be made on a case-specific basis as there are no 
definitive recommended guidelines.11 In a meta-analysis 
published by Tanis et al.9, which included 311 patients 
surgically treated for pancreatic RCC metastases, the 
authors concluded that even though there might be 
a potential selection bias, the pancreatic operation is 
justified by a remarkably high survival probability with a 
low postoperative mortality. Overall survival rates were 
estimated at 80.6% at 2 years and 72.6% at 5 years. 
However, patients should be informed about the 
substantial morbidity of pancreatic surgery, although 
it is mostly of mild clinical significance.10
Due to the indolent behavior of pancreatic 
metastatic RCC, one could consider managing these 
patients with observation and best supportive care 
alone, or by starting systemic therapy. Only a multicentric 
study comparing resection versus non-resection would 
provide the best treatment to adopt. Till such a study is 
conducted, it is believed that surgery—when technically 
feasible—represents the best therapeutic option, 
even in the presence of extrapancreatic disease or 
pancreatic multifocality.10 The combination of surgery 
with immunotherapy and antiangiogenic agents is also 
possible, although more trials are needed to formulate 
clearer evidence-based recommendations.
The patient signed an informed consent and the 
manuscript has been approved by the Ethics Committee 
of Hospital Pedro Hispano, Matosinhos, Porto, Portugal.
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